Charles "Greg" Vontz  is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17. 

Vontz's appointment expands the board to four directors, three of whom are independent.

Vontz most recently served as president and CEO of Topica Pharmaceuticals, which developed luliconazole for fungal infections of the skin, a product acquired by Medicis Pharmaceutical Corporation. Earlier, he was president and chief operating officer of Connetics Corporation, a public specialty pharmaceutical company, focusing on dermatology.  Connetics was acquired by Stiefel Pharmaceuticals in late 2006. 

Before joining Connetics, Vontz spent 12 years at Genentech in various senior marketing and product development roles.  He got his start in the pharmaceutical industry with Merck, Sharp and Dohme where he worked from 1985-1987 in sales and sales management. Vontz is also a member of the board of directors for SinuSys Corporation.